Finding New Ways of Navigating the Changing Landscape (Hedge Week)
Enko Capital: Best Credit Hedge Fund — Hedge funds must find creative ways of demonstrating their skill and ability to solve the issues their clients face. The infrastructure they employ will also be thrown into the foreground as the sector steels itself to face the challenges ahead. “As hedge funds continue to adapt to changes caused by Covid-19, the infrastructure firms employ will have to continue to be relevant and sufficient. Alongside this, firms will have to keep up with the increased levels of reporting and regulatory requirements that institutional investors expect,” comments Craig Stanley, CFA, Chief Operating Officer, Enko Capital. In fact, from an operational standpoint, the firm has deepened and extended its operational and IT infrastructure to ensure the team is able to work remotely for as long as necessary.
Two Sigma Takes Quant Expertise into Real Estate Investing (Pensions&Investments)
Two Sigma is starting a group to invest in private real estate assets as the $58 billion quant firm seeks to expand its data-science expertise into non-public markets. Rich Gomel, most recently managing partner of WeWork’s real estate investment platform, has joined as chief investment officer of Two Sigma Real Estate, the company said. Tom Hill will be chief executive officer. It will be part of the firm’s $3 billion private investment business, which Mr. Hill also leads.
2nd Circuit Wants Devil’s Advocate in Deerfield Insider Trading Case (Reuters)
A federal appeals court in New York has delayed reconsideration of two former Deerfield Management Co partners’ criminal case so it can appoint an attorney to defend the court’s prior opinion upholding their insider trading convictions, which both prosecutors and defendants have said should be largely overturned in light of a recent Supreme Court ruling. A three-judge panel of the 2nd U.S. Court of Appeals had been scheduled on Wednesday to rehear the case, which turned on whether information from the Centers for Medicare & Medicaid Services (CMS) could be considered property under fraud and conversion statutes, but postponed the hearing in an order late Friday.
Thursday 4/22 Insider Buying Report: AGL, TSP (Nasdaq.com)
On Monday, Agilon Health’s Director, Clay Richards, made a $499,100 buy of AGL, purchasing 21,700 shares at a cost of $23.00 a piece. So far Richards is in the green, up about 43.9% on their purchase based on today’s trading high of $33.10. Agilon Health is trading up about 0.9% on the day Thursday. And at Tusimple Holdings, there was insider buying on Monday, by Director Karen C. Francis who purchased 7,142 shares at a cost of $40.00 each, for a trade totaling $285,680. This buy marks the first one filed by Francis in the past year. Tusimple Holdings is trading down about 0.8% on the day Thursday. Investors have the opportunity to buy TSP even cheaper than Francis did, with shares changing hands as low as $37.41 in trading on Thursday — that’s 6.5% below Francis’s purchase price.
The President & Chief Executive Officer of Midwest Energy Emissions (Other OTC: MEEC) is Selling Shares (Analyst Ratings)
Yesterday, the President & Chief Executive Officer of Midwest Energy Emissions (MEEC), Richard Alan Macpherson, sold shares of MEEC for $599.5K. In addition to Richard Alan Macpherson, one other MEEC executive reported Sell trades in the last month. MEEC’s market cap is $83.72 million and the company has a P/E ratio of -14.40. Currently, Midwest Energy Emissions has an average volume of 242.56K. The company has a one-year high of $1.85 and a one-year low of $0.05.
Medpace Holdings Inc (MEDP) President & CEO August J. Troendle Sold $4.7 million of Shares (Guru Focus)
President & CEO of Medpace Holdings Inc, August J. Troendle, sold 26,094 shares of MEDP on 04/20/2021 at an average price of $181.94 a share. The total sale was $4.7 million. Medpace Holdings Inc is a clinical contract research organisation. It is engaged in providing scientifically-driven clinical research-based drug and medical device development services to the biotechnology, pharmaceutical and medical device industries.
